The dawn of personal genomics promises benefits and pitfalls that no one can foresee.

It could usher in an era of personalized medicine, in which drug regimens are customized for a patient’s biochemistry rather than juggled through trial and error.

It also opens up a niche for bottom-feeding companies to terrify hypochondriacs by turning dubious probabilities into Genes of Doom.